Table 2 Characteristics of patients with EOCC in the right-side and transverse-sided groups

n

1980

573

Sex

0.855

 Female

907(45.8%)

260(45.4%)

 Male

1073(54.2%)

313(54.6%)

Histology

0.728

 Non-specific adenocarcinoma

1680(84.8%)

484(84.5%)

 Specific adenocarcinoma

294(14.8%)

86(15.0%)

 Others

6(0.3%)

3(0.5%)

Pathologic stage

0.048^*

 Stage I-II

807(40.8%)

260(45.4%)

 Stage III-IV

1173 (59.2%)

313(63.6%)

Surgery of Primary Site

0.290

 Yes

1965 (99.2%)

566(98.8%)

 No

15(0.8%)

7(1.2%)

Reginal lymph node dissection

0.181

 Yes

1937(97.8%)

555(96.9%)

 No

43(2.2%)

18(3.1%)

Radiation, n (%)

0.006^*

 Yes

51(2.6%)

4(0.7%)

 No

1929(97.4)

569(99.3%)

Chemotherapy

0.716

 Yes

1217(61.5%)

357(62.3%)

 No/unknown

763(38.5%)

216(37.7%)

Bone metastasis

0.182

 Yes

6(0.3%)

4(0.7%)

 No

1974(99.7%)

569(99.3%)

Liver metastasis

0.857

 Yes

298(15.1%)

88(15.4%)

 No

1682(84.9%)

485(84.6%)

Lung metastasis

0.109

 Yes

59(3.0%%)

10(1.7%)

 No

1921 (97.0%)

563 (98.3%)

Grade

0.250

 Well and moderate

1495(75.5%)

446(77.8%)

 Poor

485(24.5%)

127(22.2%)

Pretreatment CEA level

0.081

 Negative

1190(60.1%)

321(56.0%)

 Elevated

790(39.9%)

252(44.0%)

Perineural invasion

0.978

 Yes

305(15.4%)

88(15.4%)

 No

1675(84.6%)

485(84.6%)

Tumor size

 < 0.001^*

 Median (mm)

55.00

50.00

OS month

0.222

 Median

52.00

54.00